Product Description

🔹 Product Overview
Eleftha 150 mg Injection is a prescription targeted anticancer medicine used for the treatment of HER2-positive cancers.
Contains Trastuzumab 150 mg, a monoclonal antibody that specifically targets HER2 receptors on cancer cells.
Commonly used in the management of HER2-positive breast cancer and HER2-positive gastric (stomach) cancer.

🔹 Key Uses
Treatment of HER2-positive breast cancer
Management of metastatic breast cancer
Treatment of HER2-positive gastric cancer
Used alone or in combination with chemotherapy as advised by an oncologist.

🔹 Composition
Active ingredient: Trastuzumab 150 mg
Drug class: Monoclonal Antibody
Therapeutic category: Targeted Cancer Therapy

🔹 How It Works
Targets the HER2 (Human Epidermal Growth Factor Receptor 2) protein present on certain cancer cells.
Blocks cancer cell growth and division.
Helps the immune system recognize and destroy HER2-positive cancer cells.

🔹 Key Benefits
Targeted treatment for HER2-positive cancers
Helps slow or stop cancer progression
May reduce the risk of cancer recurrence
Can improve treatment outcomes and survival rates in eligible patients
Effective when used as part of comprehensive oncology treatment plans.

🔹 Dosage and Administration
Administered only by qualified healthcare professionals.
Given as an intravenous (IV) infusion in a hospital or oncology clinic.
Dosage and treatment duration depend on cancer type, stage, and patient response.

🔹 Possible Side Effects
Fever and chills
Nausea
Headache
Fatigue
Diarrhea
Rash
Infusion-related reactions
Reduced blood cell counts
Heart-related complications in some patients.

🔹 Precautions
Use only under the supervision of an oncologist.
Regular cardiac monitoring may be required during treatment.
Not recommended during pregnancy unless specifically advised.
Inform your doctor about heart disease, liver disease, or other ongoing treatments.
Store refrigerated at 2°C–8°C and protect from freezing.